The Experts below are selected from a list of 388536 Experts worldwide ranked by ideXlab platform
J. Alfred Witjes - One of the best experts on this subject based on the ideXlab platform.
-
UroVysion compared with Cytology and quantitative Cytology in the surveillance of non-muscle-invasive bladder cancer.
European urology, 2006Co-Authors: Paula M.j. Moonen, Gerard Merkx, Pim Peelen, H.f.m. Karthaus, Dominique Smeets, J. Alfred WitjesAbstract:Abstract Objectives The multitarget fluorescence in situ hybridization probe set Vysis UroVysion, consisting of probes for chromosomes 3, 7, and 17 and for the 9p21 band, was studied to evaluate its value in the follow-up of patients with bladder cancer. The results were compared with conventional Cytology and quantitative Cytology (Quanticyt). The aim of this study was to evaluate whether UroVysion is a better adjunct to urethrocystoscopy than Cytology and quantitative Cytology. Methods UroVysion, Cytology, and quantitative Cytology were performed on 113 voided urinary samples of 105 patients under surveillance for non–muscle-invasive bladder cancer. Before urethrocystoscopy or transurethral resection of the bladder, a voided urinary sample was obtained. Results of all tests were compared to evaluate the value of UroVysion. Results Sixty-four patients had biopsy-proven urothelial cell carcinoma. Sensitivity and specificity were, respectively, 39.1% and 89.7% for UroVysion, 40.6% and 89.7% for Cytology, and 42.1% and 67.9% for quantitative Cytology. When the UroVysion test and Cytology were combined, sensitivity increased to 53.1%, but specificity decreased to 79.5%. Detection of Ta tumours was equal for Cytology and UroVysion (26.7%), detection of T1 and T2–T4 samples by UroVysion was 60% and 50%, respectively. Detection of grade 1, 2, and 3 tumours by UroVysion was 21.4%, 36.8%, and 66.7%, respectively. In four cases the UroVysion test was positive, but no abnormalities were seen at cystoscopy. Conclusions Our data suggest that the use of UroVysion provides no improvement over Cytology or quantitative Cytology in the diagnosis of recurrent non–muscle-invasive bladder tumours.
Thomas C Wright - One of the best experts on this subject based on the ideXlab platform.
-
triaging hpv positive women with p16 ki 67 dual stained Cytology results from a sub study nested into the athena trial
Gynecologic Oncology, 2017Co-Authors: Thomas C Wright, Ruediger Ridder, Catherine M Behrens, James Rangermoore, Susanne Rehm, Abha Sharma, Mark H StolerAbstract:Abstract Objectives In addition to genotyping for HPV16/18, dual-immunostaining for p16/Ki-67 has shown promise as a triage of HPV-positive women. We assessed the performance of p16/Ki-67 dual-stained Cytology for triaging HPV-positive women undergoing primary HPV screening. Methods All women ≥ 25 years with valid cervical biopsy and cobas® HPV Test results from the cross-sectional phase of ATHENA who were referred to colposcopy (n = 7727) were eligible for enrolment. p16/Ki-67 dual-stained Cytology was retrospectively performed on residual cytologic material collected into a second liquid-based Cytology vial during the ATHENA enrolment visit. The diagnostic performance of dual-stained Cytology, with or without HPV16/18 genotyping, for the detection of biopsy-confirmed cervical intraepithelial neoplasia grade 3 or worse (CIN3+) was determined and compared to Pap Cytology. Furthermore, the number of colposcopies required per CIN3+ detected was determined. Results Dual-stained Cytology was significantly more sensitive than Pap Cytology (74.9% vs. 51.9%; p Conclusions p16/Ki-67 dual-stained Cytology, either alone or combined with HPV16/18 genotyping, represents a promising approach as a sensitive and efficient triage for colposcopy of HPV-positive women when primary HPV screening is utilized.
-
cost effectiveness of human papillomavirus dna testing for cervical cancer screening in women aged 30 years or more
Obstetrics & Gynecology, 2004Co-Authors: Sue J Goldie, Jane J Kim, Thomas C WrightAbstract:OBJECTIVE To evaluate the cost-effectiveness of human papillomavirus (HPV) DNA testing as a primary screening test in combination with cervical Cytology in women aged 30 years or more. METHODS A state-transition mathematical model was used to simulate the natural history of HPV and cervical cancer in a cohort of U.S. women. Strategies included no screening and screening at different frequencies with conventional Cytology, liquid-based Cytology with HPV testing used for triage of equivocal results, and HPV DNA testing and Cytology in combination after women had reached the age of 30. Outcomes measured included cancer incidence, life expectancy, lifetime costs, and incremental cost-effectiveness ratios. RESULTS The estimated reduction in lifetime risk of cervical cancer varies from 81% to 93% depending on the screening frequency, type of Cytology, and test strategy. Every 3-year screening with liquid-based Cytology administered to women at all ages and every 3-year screening using HPV DNA testing and Cytology in combination administered to women aged 30 years or more provide equivalent or greater benefits than those provided by annual conventional Cytology and have incremental cost-effectiveness ratios of US dollars 95300 and US dollars 228700 per year of life gained, respectively. In comparison, annual screening with HPV DNA testing and Cytology in combination provides only a few hours of additional life expectancy and has a cost-effectiveness ratio of more than Us dollars 2000000 per year of life gained. CONCLUSIONS For women aged 30 years and more, every 2- or 3-year screening strategy that uses either HPV DNA testing in combination with Cytology for primary screening or Cytology with reflex HPV DNA testing for equivocal results will provide a greater reduction in cancer and be less costly than annual conventional Cytology.
Ruediger Ridder - One of the best experts on this subject based on the ideXlab platform.
-
triaging hpv positive women with p16 ki 67 dual stained Cytology results from a sub study nested into the athena trial
Gynecologic Oncology, 2017Co-Authors: Thomas C Wright, Ruediger Ridder, Catherine M Behrens, James Rangermoore, Susanne Rehm, Abha Sharma, Mark H StolerAbstract:Abstract Objectives In addition to genotyping for HPV16/18, dual-immunostaining for p16/Ki-67 has shown promise as a triage of HPV-positive women. We assessed the performance of p16/Ki-67 dual-stained Cytology for triaging HPV-positive women undergoing primary HPV screening. Methods All women ≥ 25 years with valid cervical biopsy and cobas® HPV Test results from the cross-sectional phase of ATHENA who were referred to colposcopy (n = 7727) were eligible for enrolment. p16/Ki-67 dual-stained Cytology was retrospectively performed on residual cytologic material collected into a second liquid-based Cytology vial during the ATHENA enrolment visit. The diagnostic performance of dual-stained Cytology, with or without HPV16/18 genotyping, for the detection of biopsy-confirmed cervical intraepithelial neoplasia grade 3 or worse (CIN3+) was determined and compared to Pap Cytology. Furthermore, the number of colposcopies required per CIN3+ detected was determined. Results Dual-stained Cytology was significantly more sensitive than Pap Cytology (74.9% vs. 51.9%; p Conclusions p16/Ki-67 dual-stained Cytology, either alone or combined with HPV16/18 genotyping, represents a promising approach as a sensitive and efficient triage for colposcopy of HPV-positive women when primary HPV screening is utilized.
-
p16 ki 67 dual stain Cytology in the triage of ascus and lsil papanicolaou Cytology
Cancer Cytopathology, 2011Co-Authors: D Schmidt, Christine Bergeron, Karin Denton, Ruediger RidderAbstract:BACKGROUND: The objective of this study was to analyze the diagnostic performance of a newly established immunocytochemical dual-stain protocol, which simultaneously detects p16INK4a and Ki-67 expression in cervical Cytology samples, for identifying high-grade cervical intraepithelial neoplasia (CIN2+) in women with Papanicolaou (Pap) Cytology results categorized as atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesions (LSIL). METHODS: Residual liquid-based Cytology material from 776 retrospectively collected ASCUS/LSIL cases that were available from a recent study evaluating p16 Cytology and HPV testing were subjected to p16/Ki-67 dual staining. The presence of 1 or more double-immunoreactive cell(s) was regarded as a positive test outcome, irrespective of morphology. Test results were correlated to histology follow-up. RESULTS: Sensitivity of p16/Ki-67 dual-stain Cytology for biopsy-confirmed CIN2+ was 92.2% (ASCUS) and 94.2% (LSIL), while specificity rates were 80.6% (ASCUS) and 68.0% (LSIL), respectively. Similar sensitivity/specificity profiles were found for both age groups of women aged <30 years versus women aged ≥30 years. Dual-stain Cytology showed comparable sensitivity, but significantly higher specificity, when compared with human papillomavirus (HPV) testing. CONCLUSIONS: The results of this study show that p16/Ki-67 dual-stain Cytology provided a high sensitivity for the detection of underlying CIN2+ in women with ASCUS or LSIL Pap Cytology results, comparable to the rates previously reported for HPV testing and p16 single-stain Cytology. However, the specificity of this morphology-independent interpretation of p16/Ki-67 dual-stain Cytology testing was further improved compared with the earlier p16 single-stain Cytology approach, which required morphology interpretation, and it is significantly higher when compared with HPV testing. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.
-
p16 ki 67 dual stain Cytology in the triage of ascus and lsil papanicolaou Cytology
Cancer Cytopathology, 2011Co-Authors: Dietmar Schmidt, Christine Bergeron, Karin Denton, Ruediger RidderAbstract:BACKGROUND: The objective of this study was to analyze the diagnostic performance of a newly established immunocytochemical dual-stain protocol, which simultaneously detects p16INK4a and Ki-67 expression in cervical Cytology samples, for identifying high-grade cervical intraepithelial neoplasia (CIN2+) in women with Papanicolaou (Pap) Cytology results categorized as atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesions (LSIL). METHODS: Residual liquid-based Cytology material from 776 retrospectively collected ASCUS/LSIL cases that were available from a recent study evaluating p16 Cytology and HPV testing were subjected to p16/Ki-67 dual staining. The presence of 1 or more double-immunoreactive cell(s) was regarded as a positive test outcome, irrespective of morphology. Test results were correlated to histology follow-up. RESULTS: Sensitivity of p16/Ki-67 dual-stain Cytology for biopsy-confirmed CIN2+ was 92.2% (ASCUS) and 94.2% (LSIL), while specificity rates were 80.6% (ASCUS) and 68.0% (LSIL), respectively. Similar sensitivity/specificity profiles were found for both age groups of women aged <30 years versus women aged ≥30 years. Dual-stain Cytology showed comparable sensitivity, but significantly higher specificity, when compared with human papillomavirus (HPV) testing. CONCLUSIONS: The results of this study show that p16/Ki-67 dual-stain Cytology provided a high sensitivity for the detection of underlying CIN2+ in women with ASCUS or LSIL Pap Cytology results, comparable to the rates previously reported for HPV testing and p16 single-stain Cytology. However, the specificity of this morphology-independent interpretation of p16/Ki-67 dual-stain Cytology testing was further improved compared with the earlier p16 single-stain Cytology approach, which required morphology interpretation, and it is significantly higher when compared with HPV testing. Cancer (Cancer Cytopathol) 2011;. © 2011 American Cancer Society.
Paula M.j. Moonen - One of the best experts on this subject based on the ideXlab platform.
-
UroVysion compared with Cytology and quantitative Cytology in the surveillance of non-muscle-invasive bladder cancer.
European urology, 2006Co-Authors: Paula M.j. Moonen, Gerard Merkx, Pim Peelen, H.f.m. Karthaus, Dominique Smeets, J. Alfred WitjesAbstract:Abstract Objectives The multitarget fluorescence in situ hybridization probe set Vysis UroVysion, consisting of probes for chromosomes 3, 7, and 17 and for the 9p21 band, was studied to evaluate its value in the follow-up of patients with bladder cancer. The results were compared with conventional Cytology and quantitative Cytology (Quanticyt). The aim of this study was to evaluate whether UroVysion is a better adjunct to urethrocystoscopy than Cytology and quantitative Cytology. Methods UroVysion, Cytology, and quantitative Cytology were performed on 113 voided urinary samples of 105 patients under surveillance for non–muscle-invasive bladder cancer. Before urethrocystoscopy or transurethral resection of the bladder, a voided urinary sample was obtained. Results of all tests were compared to evaluate the value of UroVysion. Results Sixty-four patients had biopsy-proven urothelial cell carcinoma. Sensitivity and specificity were, respectively, 39.1% and 89.7% for UroVysion, 40.6% and 89.7% for Cytology, and 42.1% and 67.9% for quantitative Cytology. When the UroVysion test and Cytology were combined, sensitivity increased to 53.1%, but specificity decreased to 79.5%. Detection of Ta tumours was equal for Cytology and UroVysion (26.7%), detection of T1 and T2–T4 samples by UroVysion was 60% and 50%, respectively. Detection of grade 1, 2, and 3 tumours by UroVysion was 21.4%, 36.8%, and 66.7%, respectively. In four cases the UroVysion test was positive, but no abnormalities were seen at cystoscopy. Conclusions Our data suggest that the use of UroVysion provides no improvement over Cytology or quantitative Cytology in the diagnosis of recurrent non–muscle-invasive bladder tumours.
Koichiro Sugihara - One of the best experts on this subject based on the ideXlab platform.
-
Cytology of vulvar squamous neoplasia
Acta cytologica, 1993Co-Authors: Masamichi Kashimura, Yusuke Matsuura, Toshinori Kawagoe, Naoyuki Toki, Koichiro SugiharaAbstract:Cytologic findings on various vulvar squamous lesions are described in order to elucidate the usefulness of vulvar Cytology. Lichen sclerosus, hyperplastic dystrophy and dysplasia with a few exfoliated anucleate squamous cells could not be differentiated cytologically. Numerous parakeratotic cells and dyskaryotic cells were identified in squamous cell carcinoma in situ. Three cytologic patterns were presented in cases of frankly invasive squamous cell carcinoma: negative Cytology with parakeratotic cells, suspicious Cytology with dyskaryotic cells and positive Cytology with malignant cells. Verrucous carcinoma yielded only anucleate squamous cells. Parakeratotic cells without nuclear atypia seemed to be neoplastic cells on vulvar Cytology.
